OcuSciences Secures CE Mark for OcuMet Beacon, Accelerating European Expansion

OcuSciences has announced that its advanced retinal diagnostic instrument, the OcuMet Beacon, has received CE Mark clearance, authorizing its commercialization across the European Economic Area (EEA). This regulatory milestone confirms the device's compliance with strict health, safety, and environmental standards, enabling wider clinical adoption and deployment throughout Europe.

High-Resolution Metabolic Imaging for Retinal Disease Detection

The OcuMet Beacon is built on OcuSciences’ proprietary imaging technology and is designed to deliver high-resolution metabolic insights into the retina. By capturing early changes in retinal metabolism, the system supports clinicians in the early detection and monitoring of retinal dystrophies and other vision-threatening diseases, such as age-related macular degeneration and diabetic retinopathy.

“Securing CE clearance is a major milestone for OcuSciences and reflects our dedication to advancing the standard of care in ophthalmology,” said Kurt Riegger, CEO of OcuSciences.
“The growing adoption of our technology by leading ophthalmic clinical centers across Europe highlights its unique value and diagnostic potential to improve disease detection and management and particularly helpful in monitoring treatment.”

European Deployments Underway in Clinical and Research Settings

Following CE approval, OcuSciences has initiated the deployment of OcuMet Beacon units across clinical and research institutions in Germany, England, and Wales. These installations will support both clinical diagnostics and academic research, allowing early adopters to integrate the device into ongoing studies and evaluate its real-world performance and impact on retinal imaging innovation.